SERUM CHROMOGRANIN A - A MARKER FOR HORMONE-REFRACTORY CARCINOMA OF PROSTATE - AND FOR PROGNOSIS

被引：0
|
作者：
Bhattacharyya, G. S. [1 ]
Singh, J. K. [2 ]
Singh, M. [2 ]
Basu, S. [3 ]
Vaid, A. K. [4 ]
Parikh, P. [5 ]
Malhotra, H. [6 ]
Babu, K. G. [7 ]
Mukherjhee, S. [8 ]
机构：
[1] Adv Medicare Res Inst Hosp, Kolkata, West Bengal, India
[2] Mahavir Canc Sansthan, Oncol, Patna, Bihar, India
[3] Adv Medicare Res Inst, Kolkata, India
[4] Medicity, Hod Oncol, New Delhi, India
[5] Icon Aro, Bombay, Maharashtra, India
[6] SMS Med Coll Hosp, Jaipur, Rajasthan, India
[7] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India
[8] Biospecialities, Pathol & Biochem, Kolkata, India
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [1] Chromogranin A predicts development of hormone-refractory prostate cancer
    [J]. Nature Clinical Practice Urology, 2007, 4 (11): : 581 - 581
  • [2] Increase of circulating chromogranin a in patients with hormone-refractory prostate cancer
    不详
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [3] Treatment of hormone-refractory prostate carcinoma
    Fournier, G
    [J]. EUROPEAN UROLOGY, 1996, 30 : 32 - 37
  • [4] AUO Study of hormone-refractory prostate carcinoma
    Rexer, H.
    [J]. ONKOLOGE, 2007, 13 (07): : 644 - 644
  • [5] Treatment of hormone-refractory prostate carcinoma - Discussion
    Jocham, D
    Tunn
    Thon
    Debruyne
    Bono
    Mazeman
    Minardi
    Schulman
    Montironi
    [J]. EUROPEAN UROLOGY, 1996, 30 : 38 - 39
  • [6] Treatment of hormone-refractory carcinoma of the prostate with mitoxantrone
    Otto, T
    Rembrink, K
    Goepel, M
    Krege, S
    MeyerSchwickerath, M
    Rubben, H
    [J]. UROLOGE-AUSGABE A, 1996, 35 (02): : 142 - 145
  • [7] Weekly docetaxel in hormone-refractory prostate carcinoma
    Lupo, G.
    Buemi, G. P. B.
    Marabello, G.
    Gnani, A.
    Leone, A.
    Maniaci, V
    Altavilla, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI83
  • [8] Treatment options in hormone-refractory metastatic prostate carcinoma
    Fusi, A
    Procopio, G
    Della Torre, S
    Ricotta, R
    Bianchini, G
    Salvioni, R
    Ferrari, L
    Martinetti, A
    Savelli, G
    Villa, S
    Bajetta, E
    [J]. TUMORI JOURNAL, 2004, 90 (06): : 535 - 546
  • [9] Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    Smith, DC
    Dunn, RL
    Strawderman, MS
    Pienta, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1835 - 1843
  • [10] Prognostic role of chromogranin A expression for docetaxel response in hormone-refractory metastatic prostate cancer
    Gernone, A.
    Trabucco, S.
    Troccoli, G.
    Pagliarulo, V.
    Pagliarulo, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345